Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023.

Abstract

Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has profoundly changed the management of relapsed/refractory large-B-cell lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell products for LBCL: axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Two of these (axi-cel & liso-cel) are approved for use in the second-line setting under certain conditions. As CAR T-cell therapy continues to define a new role in the treatment armamentarium for LBCL, questions remain regarding which product to use and how to sequence CAR T-cell therapy with other therapeutic options. Here we will briefly review the key features of each FDA-approved anti-CD19 CAR T-cell product and the data that led to regulatory approval for each. Next, we will focus on the recent landmark studies that have established the use of CAR T-cell therapy as second-line treatment. While no direct prospective head-to-head comparisons exist of the 3 constructs, we will review some retrospective studies that suggest some emerging differences between the products. Lastly, we will turn our attention to the horizon as we explore some of the ongoing questions of how to best leverage the curative potential of CAR T-cell therapy for the most effective management of LBCL. These areas include the consideration of CAR T-cell therapy in the frontline setting, the optimal timing for CAR T-cell referral, the optimal bridging approach, and how to continue advancing novel CAR T-cell approaches in the context of the current treatment landscape.

• Authors: Christine E Ryan, Caron A Jacobson
• Journal: Seminars in hematology (Semin Hematol) Vol. 60 Issue 5 Pg. 322-328 (Nov 2023) ISSN: 1532-8686 [Electronic] United States
• PMID: 38199906 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Receptors, Chimeric Antigen

Topics

• Humans
• Immunotherapy, Adoptive
• Prospective Studies
• Receptors, Chimeric Antigen
• Retrospective Studies
• Cell- and Tissue-Based Therapy
• Lymphoma, Large B-Cell, Diffuse